Detalhe da pesquisa
1.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815271
2.
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Blood
; 134(13): 1024-1036, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331917
3.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Br J Haematol
; 189(4): 650-660, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32180219
4.
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
EClinicalMedicine
; 56: 101779, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36618900
5.
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
J Clin Oncol
; 40(1): 52-62, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34606378
6.
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Leuk Lymphoma
; 62(9): 2094-2106, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33856277
7.
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
Clin Cancer Res
; 27(21): 5793-5800, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380643
8.
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
Neuro Oncol
; 20(2): 249-258, 2018 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29016998
9.
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
Neuro Oncol
; 20(2): 259-267, 2018 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29036345
10.
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Neuro Oncol
; 20(10): 1411-1418, 2018 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29660005